LX101

PreclinicalSmall molecule

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

LX101 is one of 4 small molecule programs targeting Gene Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gene TherapyNot yet recruiting

Gene TherapyPreclinical

Not yet recruiting

Competition

Competitive Landscape

9 competitors in Gene Therapy

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Phase 2

2 2

BMN 333

BioMarin Pharmaceutical

Phase 2

1 3

Raav2-ND4

BBin Li

Preclinical

1 4

LX101

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2038

N/ANot yet recruiting

Gene Therapy

NCT06024057

Clinical

Trials by Indication[1]

Gene Therapy1 trial

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT06024057·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LX101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LX101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LX101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

LX101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2038

Trials by Indication[1]

Gene Therapy1 trial

References

Drug Info

Quick Facts

Related News